Systemic Autoinflammatory Diseases-Clinical Rheumatic Challenges
Autoinflammation, as a relatively new field in clinical rheumatology, has gained an increasing importance in recent years. The number of identified entities and affected patients has gradually increased, and some of the involved pathways have already been identified. This progress allows a deeper un...
Spremljeno u:
| Format: | Online |
|---|---|
| Jezik: | engleski |
| Izdano: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Teme: | |
| Online pristup: | ONIX_20220111_9783036525600_908 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
| _version_ | 1869518043675099136 |
|---|---|
| collection | Directory of Open Access Books |
| description | Autoinflammation, as a relatively new field in clinical rheumatology, has gained an increasing importance in recent years. The number of identified entities and affected patients has gradually increased, and some of the involved pathways have already been identified. This progress allows a deeper understanding of closely linked diseases, namely, inflammasomopathies, interferonopathies, Relo-pathies, and proteasome associated syndromes. These insights have not only improved their classification but also helped to identify new treatment targets of pro-inflammatory cytokines, including IL-1ß, IL-6, interferon-, and TNF-alpha. Nevertheless, there is still a high medical need, especially in reliable outcome measures, for confirmation of data from controlled clinical trials and, finally, also for long-term experience from registers. This issue welcomes all types of papers on the broad spectrum of clinical characteristics, prognosis, pathophysiology, and treatment of autoinflammatory diseases. The goal of this Special Issue is to further raise awareness of autoinflammatory processes and to better separate them from well-established autoimmune diseases. It is clear that we have entered a new age in this complex field, linking rheumatology even closer to immunology. |
| format | Online |
| id | doab-20.500.12854ir-77076 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-770762024-03-30T23:22:14Z Systemic Autoinflammatory Diseases-Clinical Rheumatic Challenges Feist, Eugen gout febuxostat colchicine hepatotoxicity prophylaxis myositis inflammatory idiopathic myopathy dysphagia aspiration pneumonia immunoglobulin G4-related orbital disease (IgG4-ROD) orbital lymphoma (OL) computed tomography (CT) Hounsfield unit imaging autoinflammation arthritis CAPS FCAS MWS CINCA NOMID hearing loss urticarial-like rash autoinflammatory disease anti-IL-1 treatment rheumatoid arthritis synovitis neoplasms edema inflammation new genetic variant monogenic autoinflammatory syndrome diagnostic delay anakinra damage index genetic inheritance personalized therapy Interleukin-1 autoinflammatory diseases FMF coronavirus SARS-CoV-2 antibody response adult-onset Still’s disease autoinflammatory disorder systemic-onset juvenile idiopathic arthritis haemophagocytic lymphohistiocytosis macrophage activation syndrome IFN-γ JAK inhibitor proliferation DNA damage repair γH2AX PBMCs T lymphocytes proteasome autoimmune proteasome-associated autoinflammatory syndrome therapy IL-1 inhibitors NGS SURF spondyloarthritis human leukocyte antigen undifferentiated enthesitis and/or arthritis ASAS classification criteria clinical management canakinumab cytokines n/a thema EDItEUR::M Medicine and Nursing Autoinflammation, as a relatively new field in clinical rheumatology, has gained an increasing importance in recent years. The number of identified entities and affected patients has gradually increased, and some of the involved pathways have already been identified. This progress allows a deeper understanding of closely linked diseases, namely, inflammasomopathies, interferonopathies, Relo-pathies, and proteasome associated syndromes. These insights have not only improved their classification but also helped to identify new treatment targets of pro-inflammatory cytokines, including IL-1ß, IL-6, interferon-, and TNF-alpha. Nevertheless, there is still a high medical need, especially in reliable outcome measures, for confirmation of data from controlled clinical trials and, finally, also for long-term experience from registers. This issue welcomes all types of papers on the broad spectrum of clinical characteristics, prognosis, pathophysiology, and treatment of autoinflammatory diseases. The goal of this Special Issue is to further raise awareness of autoinflammatory processes and to better separate them from well-established autoimmune diseases. It is clear that we have entered a new age in this complex field, linking rheumatology even closer to immunology. 2022-01-11T13:51:27Z 2022-01-11T13:51:27Z 2021 book ONIX_20220111_9783036525600_908 9783036525600 9783036525617 https://directory.doabooks.org/handle/20.500.12854/77076 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/4695 https://mdpi.com/books/pdfview/book/4695 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-2561-7 10.3390/books978-3-0365-2561-7 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036525600 9783036525617 266 Basel, Switzerland open access |
| spellingShingle | gout febuxostat colchicine hepatotoxicity prophylaxis myositis inflammatory idiopathic myopathy dysphagia aspiration pneumonia immunoglobulin G4-related orbital disease (IgG4-ROD) orbital lymphoma (OL) computed tomography (CT) Hounsfield unit imaging autoinflammation arthritis CAPS FCAS MWS CINCA NOMID hearing loss urticarial-like rash autoinflammatory disease anti-IL-1 treatment rheumatoid arthritis synovitis neoplasms edema inflammation new genetic variant monogenic autoinflammatory syndrome diagnostic delay anakinra damage index genetic inheritance personalized therapy Interleukin-1 autoinflammatory diseases FMF coronavirus SARS-CoV-2 antibody response adult-onset Still’s disease autoinflammatory disorder systemic-onset juvenile idiopathic arthritis haemophagocytic lymphohistiocytosis macrophage activation syndrome IFN-γ JAK inhibitor proliferation DNA damage repair γH2AX PBMCs T lymphocytes proteasome autoimmune proteasome-associated autoinflammatory syndrome therapy IL-1 inhibitors NGS SURF spondyloarthritis human leukocyte antigen undifferentiated enthesitis and/or arthritis ASAS classification criteria clinical management canakinumab cytokines n/a thema EDItEUR::M Medicine and Nursing Systemic Autoinflammatory Diseases-Clinical Rheumatic Challenges |
| title | Systemic Autoinflammatory Diseases-Clinical Rheumatic Challenges |
| title_full | Systemic Autoinflammatory Diseases-Clinical Rheumatic Challenges |
| title_fullStr | Systemic Autoinflammatory Diseases-Clinical Rheumatic Challenges |
| title_full_unstemmed | Systemic Autoinflammatory Diseases-Clinical Rheumatic Challenges |
| title_short | Systemic Autoinflammatory Diseases-Clinical Rheumatic Challenges |
| title_sort | systemic autoinflammatory diseases clinical rheumatic challenges |
| topic | gout febuxostat colchicine hepatotoxicity prophylaxis myositis inflammatory idiopathic myopathy dysphagia aspiration pneumonia immunoglobulin G4-related orbital disease (IgG4-ROD) orbital lymphoma (OL) computed tomography (CT) Hounsfield unit imaging autoinflammation arthritis CAPS FCAS MWS CINCA NOMID hearing loss urticarial-like rash autoinflammatory disease anti-IL-1 treatment rheumatoid arthritis synovitis neoplasms edema inflammation new genetic variant monogenic autoinflammatory syndrome diagnostic delay anakinra damage index genetic inheritance personalized therapy Interleukin-1 autoinflammatory diseases FMF coronavirus SARS-CoV-2 antibody response adult-onset Still’s disease autoinflammatory disorder systemic-onset juvenile idiopathic arthritis haemophagocytic lymphohistiocytosis macrophage activation syndrome IFN-γ JAK inhibitor proliferation DNA damage repair γH2AX PBMCs T lymphocytes proteasome autoimmune proteasome-associated autoinflammatory syndrome therapy IL-1 inhibitors NGS SURF spondyloarthritis human leukocyte antigen undifferentiated enthesitis and/or arthritis ASAS classification criteria clinical management canakinumab cytokines n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | gout febuxostat colchicine hepatotoxicity prophylaxis myositis inflammatory idiopathic myopathy dysphagia aspiration pneumonia immunoglobulin G4-related orbital disease (IgG4-ROD) orbital lymphoma (OL) computed tomography (CT) Hounsfield unit imaging autoinflammation arthritis CAPS FCAS MWS CINCA NOMID hearing loss urticarial-like rash autoinflammatory disease anti-IL-1 treatment rheumatoid arthritis synovitis neoplasms edema inflammation new genetic variant monogenic autoinflammatory syndrome diagnostic delay anakinra damage index genetic inheritance personalized therapy Interleukin-1 autoinflammatory diseases FMF coronavirus SARS-CoV-2 antibody response adult-onset Still’s disease autoinflammatory disorder systemic-onset juvenile idiopathic arthritis haemophagocytic lymphohistiocytosis macrophage activation syndrome IFN-γ JAK inhibitor proliferation DNA damage repair γH2AX PBMCs T lymphocytes proteasome autoimmune proteasome-associated autoinflammatory syndrome therapy IL-1 inhibitors NGS SURF spondyloarthritis human leukocyte antigen undifferentiated enthesitis and/or arthritis ASAS classification criteria clinical management canakinumab cytokines n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20220111_9783036525600_908 |